Brook Jackson

Brook Jackson Website (Whistleblower)
File:Brook Jackson.png
Exposed	COVID-19/Vaccines
A whistleblower who witnessed numerous violations of standard operating procedure in the experiments carried out regards COVID jabs

Brook Jackson is a whistleblower who witnessed numerous violations of standard operating procedure in what she thought were trials of the COVID jabs' "safety and efficacy". She reports that she "repeatedly informed her superiors of poor laboratory management, patient safety concerns and data integrity issues" during the two weeks she was employed by Ventavia in September 2020. She gave a cache of information to the BMJ, which published a piece on her claims.

Court case

In January 2021 Jackson sued Pfizer, Ventavia and ICON PLC, another Pfizer contractor. She charged that "Ventavia’s trial protocol and regulatory violations were so widespread, in fact, that [she] observed them on a near-daily basis during her brief employment period", and that the companies committed numerous violations of the False Claims Act (FCA), alleging "a deeply flawed clinical trial that violated FDA regulations".

Other Transaction Authority

Brook Jackson's case is cited by researchers including Sasha Latypova as having highlighted the USDoD's use of the Other Transaction Authority to order the jabs as prototype countermeasures, avoiding contract and pharmaceutical laws that would have applied to them if they had been classed as medical treatments.

Case dismissed

The defendants moved to dismiss the case. On January 18, 2022, the United States declined to intervene in this action, but on October 4, 2022, the United States took the unusual step of filing a Statement of Interest Supporting Dismissal of the Amended Complaint.

In his March 31 ruling, U.S. District judge Michael Truncale dismissed the case. His ruling cited the precedent that "if the Government pays a particular claim in full despite its actual knowledge that certain requirements were violated, that is very strong evidence that those requirements are not material."

Conflicting loyalties

Daniel Greer wrote in May 2024 that "a former FDA lawyer who worked at the agency when Jackson’s complaint was filed has moved to the DOJ and is now representing the government in its attempt to shut down the suit, raising concerns about regulatory capture and the use of government to shield companies from accountability."